241 results
Page 2 of 13
8-K
EX-2.1
2v4oa
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.1
u9of3p
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.1
atrid51j1
31 Oct 23
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
5:18pm
8-K
EX-99.2
wlumo 4s5njxip
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.1
1euyqa2r
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.2
k7wvbeph9bm uhyx4
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
EX-99.1
55fir
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
EX-99.1
jhv6fhkxdpax5f8g4db
30 Aug 23
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
7:14am
8-K
03h3m bu856cdzxty
30 Aug 23
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
7:14am
8-K
EX-99.1
d3r5y9rfy8ep8w 3h
26 Jul 23
Alkermes plc Reports Second Quarter 2023 Financial Results
7:06am
8-K
EX-99.2
rl0ktlsu028qpyaix
26 Jul 23
Alkermes plc Reports Second Quarter 2023 Financial Results
7:06am
DEFA14A
uxvfwbkk05ofuu89
26 Jun 23
Additional proxy soliciting materials
7:05am
DEFA14A
i2zyhddeixwbi3
21 Jun 23
Additional proxy soliciting materials
8:06am
DEFA14A
xzis msqoegdr761275
20 Jun 23
Additional proxy soliciting materials
7:11am
DEFA14A
7yr9 3bevw9tx5btdd
13 Jun 23
Additional proxy soliciting materials
7:08am